Traduction de «Gérer la logistique des produits médicaux » (Français → Anglais) :

RECALLS the Council conclusions on the ‘Reflection process on modern, responsive and sustainable health systems’, adopted on 10 December 2013 (3), and the Council conclusions on the economic crisis and healthcare, adopted on 20 June 2014 (4), which advocate the need for cooperation, while fully respecting areas of Member States’ competence, on strategies to effectively manage expenditure on pharmaceuticals and medical devices, while ensuring equitable access to effective medicines within sustainable national healthcare systems;

RECALLS the Council conclusions on the ‘Reflection process on modern, responsive and sustainable health systems’, adopted on 10 December 2013 , and the Council conclusions on the economic crisis and healthcare, adopted on 20 June 2014 , which advocate the need for cooperation, while fully respecting areas of Member States’ competence, on strategies to effectively manage expenditure on pharmaceuticals and medical devices, while ensuring equitable access to effective medicines within sustainable national healthcare systems.

In May, Livingston Healthcare Services Inc., an Ontario based health products distributor, opened a new logistics facility in Oakville.

ECHO's partner in this project is the NGO Paz y Tercer Mundo (Spain) which will be responsible for distributing medical, food and logistical products and providing health training for local staff.

The key deliverables of the initiative include an assessment of the TPP cost-recovery initiative as it relates to the Treasury Board cost-recovery policy, and the public and private benefits that have derived from it; a thorough assessment of the current cost-recovery initiative costing model used by the TPP, including a comparison of other regulatory regimes and justifications, identification of any gaps in the current cost-recovery initiative, and the contribution of fees to the delivery of an efficient service; an evaluation of whether the cost-recovery initiative has had an impact on the TPP's performance, taking into consideration ...[+++] previous performance commitments, other jurisdictions' experience, options for improving feedback and/or communication mechanisms for stakeholders to foster transparency and accountability, and constraints that might limit my program's ability to manage the cost-recovery initiative and thereby the efficient operations of its programs; an assessment of the direct, indirect, and cumulative impacts of the cost-recovery initiative on therapeutic products industries, on consumers and the health care system, and on the TPP itself, and the development of a rigorous methodology and relevant data sources for a follow-up assessment of the impact of planned fees on the medical devices regulation area; and finally, a systematic review of lessons learned from other jurisdictions and options for operational and/or organizational alternatives and/or modifications to improve the management of the TPP cost recovery initiative.